Purpose: Curing all children with
brain tumors will require an understanding of how each subtype responds to conventional treatments and how best to combine existing and novel
therapies. It is extremely challenging to acquire this knowledge in the clinic alone, especially among patients with rare
tumors. Therefore, we developed a preclinical
brain tumor platform to test combinations of conventional and novel
therapies in a manner that closely recapitulates clinic trials.Experimental Design: A multidisciplinary team was established to design and conduct neurosurgical, fractionated
radiotherapy and
chemotherapy studies, alone or in combination, in accurate mouse models of supratentorial
ependymoma (SEP) subtypes and
choroid plexus carcinoma (
CPC). Extensive drug repurposing screens, pharmacokinetic, pharmacodynamic, and efficacy studies were used to triage active compounds for combination preclinical trials with "standard-of-care" surgery and
radiotherapy.Results: Mouse models displayed distinct patterns of response to surgery, irradiation, and
chemotherapy that varied with
tumor subtype. Repurposing screens identified 3-hour infusions of
gemcitabine as a relatively nontoxic and efficacious treatment of SEP and
CPC. Combination neurosurgery, fractionated irradiation, and
gemcitabine proved significantly more effective than surgery and irradiation alone, curing one half of all animals with aggressive forms of SEP.Conclusions: We report a comprehensive preclinical trial platform to assess the therapeutic activity of conventional and novel treatments among rare
brain tumor subtypes. It also enables the development of complex, combination treatment regimens that should deliver optimal trial designs for clinical testing. Postirradiation
gemcitabine infusion should be tested as new treatments of SEP and
CPC. Clin
Cancer Res; 24(7); 1654-66. ©2018 AACR.